Clozapine and N-Methyl-d-Aspartate have positive modulatory actions on their respective discriminative stimulus properties in C57BL/6 mice

European Journal of Pharmacology

Volumn 650, Issue 2-3, 2011, Pages 579-585

  Vunck, Sarah A ^a   Wiebelhaus, Jason M ^a   Arnt, Jørn ^b   Porter, Joseph H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b H LUNDBECK A S   (Denmark)

Author keywords

C57BL 6 mouse; Clozapine; Drug discrimination; Glutamate; N Methyl d Aspartate (N Methyl d aspartate); Prazosin

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; CLOZAPINE; N METHYL DEXTRO ASPARTIC ACID; PRAZOSIN;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; IN VIVO STUDY; MALE; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DISCRIMINATION (PSYCHOLOGY); DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID AGONISTS; GENERALIZATION, STIMULUS; MALE; MICE; MICE, INBRED C57BL; N-METHYLASPARTATE; PRAZOSIN;

EID: 78651089115     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.10.022     Document Type: Article

References (68)

1. M. Amargos-Bosch, A. Adell, A. Bortolozzi, and F. Artigas Stimulation of alpha1-adrenoceptors in the rat medial prefrontal cortex increases the local in vivo 5-hydroxytryptamine release: reversal by antipsychotic drugs J. Neurochem. 87 2003 831 842 (Pubitemid 37444559)
2. M. Amargos-Bosch, X. Lopez-Gil, F. Artigas, and A. Adell Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine Int. J. Neuropsychopharmacol. 9 2006 565 573
3. J.D. Andersen, and B. Pouzet Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of D-serine Neuropsychopharmacology 29 2004 1080 1090
4. 1-Andrenoceptor Antagonists Substitute for the Discriminative Stimulus Properties of NMDA in Rats 1997 Society for Neuroscience New Orleans
5. J. Arnt, and T. Skarsfeldt Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence Neuropsychopharmacology 18 1998 63 101
6. J. Arnt, B. Bang-Andersen, R. Dias, and K.P. Bogeso Strategies for pharmacotherapy of schizophrenia Drugs Future 33 9 2008 777 791
7. C.I. Bliss Statistics in Biology 1967 McGraw-Hill New York
8. F.P. Bymaster, D.O. Calligaro, J.F. Falcone, R.D. Marsh, N.A. Moore, N.C. Tye, P. Seeman, and D.T. Wong Radioreceptor binding profile of the atypical antipsychotic olanzapine Neuropsychopharmacology 14 1996 87 96
9. S.M. Clinton, and J.H. Meador-Woodruff Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder Neuropsychopharmacology 29 2004 1353 1362
10. D.A. Collier, and T. Li The genetics of schizophrenia: glutamate not dopamine? Eur. J. Pharmacol. 480 2003 177 184
11. D.A. Cory-Slechta, M.J. Pokora, and J.L. Johnson Postweaning lead exposure enhances the stimulus properties of N-methyl-D-aspartate: possible dopaminergic involvement? Neurotoxicology 17 1996 509 521
12. J.T. Coyle Glutamate and schizophrenia: beyond the dopamine hypothesis Cell. Mol. Neurobiol. 26 2006 365 384
13. M.F. Egan, R.E. Straub, T.E. Goldberg, I. Yakub, J.H. Callicott, A.R. Hariri, V.S. Mattay, A. Bertolino, T.M. Hyde, C. Shannon-Weickert, M. Akil, J. Crook, R.K. Vakkalanka, R. Balkissoon, R.A. Gibbs, J.E. Kleinman, and D.R. Weinberger Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia Proc. Natl Acad. Sci. USA 101 2004 12604 12609
14. S. Erhardt, and G. Engberg Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid Acta Physiol. Scand. 175 2002 45 53
15. K. Extance, and A.J. Goudie Inter-animal olfactory cues in operant drug discrimination procedures in rats Psychopharmacol. Berl 73 1981 363 371
16. J.A. Goas, and J.E. Boston Jr. Discriminative stimulus properties of clozapine and chlorpromazine Pharmacol. Biochem. Behav. 8 1978 235 241
17. D.C. Goff, G. Tsai, J. Levitt, E. Amico, D. Manoach, D.A. Schoenfeld, D.L. Hayden, R. McCarley, and J.T. Coyle A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia Arch. Gen. Psychiatry 56 1999 21 27 (Pubitemid 29055046)
18. A. Goldstein Biostatistics; An Introductory Text 1964 McMillian Company New York
19. P.J. Harrison, and M.J. Owen Genes for schizophrenia? Recent findings and their pathophysiological implications Lancet 361 2003 417 419
20. H. Hippius A historical perspective of clozapine J. Clin. Psychiatry 60 Suppl 12 1999 22 23
21. T. Hirose, Y. Uwahodo, S. Yamada, T. Miwa, T. Kikuchi, H. Kitagawa, K.D. Burris, C.A. Altar, and T. Nabeshima Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile J. Psychopharmacol. 18 2004 375 383
22. K.E. Jardemark, I. Ninan, X. Liang, and R.Y. Wang Protein kinase C is involved in clozapine's facilitation of N-methyl-D-aspartate- and electrically evoked responses in pyramidal cells of the medial prefrontal cortex Neuroscience 118 2003 501 512 (Pubitemid 36423264)
23. D.C. Javitt Glycine modulators in schizophrenia Curr. Opin. Investig. Drugs 3 2002 1067 1072
24. D.C. Javitt Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification Curr. Opin. Drug Dis. Dev. 12 2009 468 478
25. P.W. Kalivas, P. Duffy, and J. Barrow Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes J. Pharmacol. Exp. Ther. 251 1989 378 387
26. J.T. Kantrowitz, A.K. Malhotra, B. Cornblatt, G. Silipo, A. Balla, R.F. Suckow, C. Cyril D'Souza, J. Saksa, S.W. Woods, and D.C. Javitt High dose D-serine in the treatment of schizophrenia Schizophr. Res. 121 1-3 2010 125 130
27. B.M. Kelley, and J.H. Porter The role of muscarinic cholinergic receptors in the discriminative stimulus properties of clozapine in rats Pharmacol. Biochem. Behav. 57 1997 707 719
28. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner, G.R. Heninger, M.B. Bowers Jr., and D.S. Charney Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch. Gen. Psychiatry 51 1994 199 214
29. V. Labrie, T. Lipina, and J.C. Roder Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia Psychopharmacol. Berl 200 2008 217 230
30. H.Y. Lane, C.H. Lin, Y.J. Huang, C.H. Liao, Y.C. Chang, and G.E. Tsai A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia Int. J. Neuropsychopharmacol. 13 2010 451 460
31. U.E. Lang, I. Puls, D.J. Muller, N. Strutz-Seebohm, and J. Gallinat Molecular mechanisms of schizophrenia Cell. Physiol. Biochem. 20 2007 687 702
32. C. Mehler-Wex, P. Riederer, and M. Gerlach Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder Neurotox. Res. 10 2006 167 179
33. H.Y. Meltzer, and S.R. McGurk The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia Schizophr. Bull. 25 1999 233 255
34. H.Y. Meltzer, S. Matsubara, and J.C. Lee The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs Psychopharmacol. Bull. 25 1989 390 392
35. H.Y. Meltzer, P.A. Thompson, M.A. Lee, and R. Ranjan Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment Neuropsychopharmacology 14 1996 27S 33S
36. L.D. Middaugh, J.P. Favara, W.O. Boggan, and A.J. Stringer Discriminative properties of phencyclidine in mice: generalization to ketamine and monohydroxy metabolites Psychopharmacol. Berl 96 1988 381 384
37. B. Moghaddam Bringing order to the glutamate chaos in schizophrenia Neuron 40 2003 881 884
38. S. Murase, J. Grenhoff, G. Chouvet, F.G. Gonon, and T.H. Svensson Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo Neurosci. Lett. 157 1993 53 56
39. National Research Council, 1996. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press.
40. I. Ninan, K.E. Jardemark, X. Liang, and R.Y. Wang Calcium/calmodulin- dependent kinase II is involved in the facilitating effect of clozapine on NMDA- and electrically evoked responses in the medial prefrontal cortical pyramidal cells Synapse 47 2003 285 294 (Pubitemid 36160121)
41. I. Ninan, K.E. Jardemark, and R.Y. Wang Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex Synapse 48 2003 66 79 (Pubitemid 36374000)
42. I. Ninan, K.E. Jardemark, and R.Y. Wang Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of N-methyl-D-aspartate receptors in pyramidal cells of the rat medial prefrontal cortex Neuropharmacology 44 2003 462 472
43. R. Ortmann, J. Meisberger, S. Bischoff, K. Hauser, H. Bittiger, and P. Waldmeier The clozapine cue in rats as tools for the characteristics of neuroleptics. Abstract Psychopharmacology 89 1986 S47
44. D.A. Overton Comparison of the degree of discriminability of various drugs using the T-maze drug discrimination paradigm Psychopharmacol. Berl 76 1982 385 395
45. S.T. Patil, L. Zhang, F. Martenyi, S.L. Lowe, K.A. Jackson, B.V. Andreev, A.S. Avedisova, L.M. Bardenstein, I.Y. Gurovich, M.A. Morozova, S.N. Mosolov, N.G. Neznanov, A.M. Reznik, A.B. Smulevich, V.A. Tochilov, B.G. Johnson, J.A. Monn, and D.D. Schoepp Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial Nat. Med. 13 2007 1102 1107
46. S.D. Philibin, A.J. Prus, A.L. Pehrson, and J.H. Porter Serotonin receptor mechanisms mediate the discriminative stimulus properties of the atypical antipsychotic clozapine in C57BL/6 mice Psychopharmacol. Berl 180 2005 49 56
47. S.D. Philibin, D.M. Walentiny, S.A. Vunck, A.J. Prus, H.Y. Meltzer, and J.H. Porter Further characterization of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in C57BL/6 mice: role of 5-HT(2A) serotonergic and alpha (1) adrenergic antagonism Psychopharmacol. Berl 203 2009 303 315
48. J.H. Porter, S.A. Varvel, R.E. Vann, S.D. Philibin, and L.E. Wise Clozapine discrimination with a low training dose distinguishes atypical from typical antipsychotic drugs in rats Psychopharmacol. Berl 149 2000 189 193
49. J.H. Porter, D.M. Walentiny, S.D. Philibin, S.A. Vunck, and J.C. Crabbe A comparison of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in DBA/2 and C57BL/6 inbred mice Behav. Pharmacol. 19 2008 530 542
50. A.J. Prus, L.E. Baker, and H.Y. Meltzer Discriminative stimulus properties of 1.25 and 5.0 mg/kg doses of clozapine in rats: examination of the role of dopamine, serotonin, and muscarinic receptor mechanisms Pharmacol. Biochem. Behav. 77 2004 199 208
51. A.J. Prus, S.D. Philibin, A.L. Pehrson, and J.H. Porter Generalization to atypical antipsychotic drugs depends on training dose in rats trained to discriminate 1.25 mg/kg clozapine versus 5.0 mg/kg clozapine versus vehicle in a three-choice drug discrimination task Behav. Pharmacol. 16 2005 511 520
52. A.J. Prus, S.D. Philibin, A.L. Pehrson, and J.H. Porter Discriminative stimulus properties of the atypical antipsychotic drug clozapine in rats trained to discriminate 1.25 mg/kg clozapine vs. 5.0 mg/kg clozapine vs. vehicle Behav. Pharmacol. 17 2006 185 194
53. W.J. Schmidt, and T.L. Volz Clozapine-like discriminate stimulus effects of N-methyl-D-aspartate (NMDA) Psychopharmacology (Berl) Supplemental: Abstract: BAP and EBPS Joint Meeting, Cambridge 1992
54. A. Schotte, P.F. Janssen, W. Gommeren, W.H. Luyten, P. Van Gompel, A.S. Lesage, K. De Loore, and J.E. Leysen Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding Psychopharmacol. Berl 124 1996 57 73
55. L. Schwieler, G. Engberg, and S. Erhardt Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex Synapse 52 2004 114 122
56. L. Schwieler, K.R. Linderholm, L.K. Nilsson-Todd, S. Erhardt, and G. Engberg Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area Life Sci. 83 2008 170 175
57. P. Seeman Dopamine receptors and the dopamine hypothesis of schizophrenia Synapse 1 1987 133 152
58. K.L. Shelton, and R.L. Balster Effects of abused inhalants and GABA-positive modulators in dizocilpine discriminating inbred mice Pharmacol. Biochem. Behav. 79 2004 219 228
59. S.S. Shim, M.D. Hammonds, and B.S. Kee Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site Eur. Arch. Psychiatry Clin. Neurosci. 258 2008 16 27
60. H. Stefansson, E. Sigurdsson, V. Steinthorsdottir, S. Bjornsdottir, T. Sigmundsson, S. Ghosh, J. Brynjolfsson, S. Gunnarsdottir, O. Ivarsson, T.T. Chou, O. Hjaltason, B. Birgisdottir, H. Jonsson, V.G. Gudnadottir, E. Gudmundsdottir, A. Bjornsson, B. Ingvarsson, A. Ingason, S. Sigfusson, H. Hardardottir, R.P. Harvey, D. Lai, M. Zhou, D. Brunner, V. Mutel, A. Gonzalo, G. Lemke, J. Sainz, G. Johannesson, T. Andresson, D. Gudbjartsson, A. Manolescu, M.L. Frigge, M.E. Gurney, A. Kong, J.R. Gulcher, H. Petursson, and K. Stefansson Neuregulin 1 and susceptibility to schizophrenia Am. J. Hum. Genet. 71 2002 877 892
61. T.H. Svensson Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs Brain Res. Rev. 31 2000 320 329
62. T.H. Svensson Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 1145 1158
63. D.M. Taylor Aripiprazole: a review of its pharmacology and clinical use Int. J. Clin. Pract. 57 2003 49 54
64. M. Toda, and A. Abi-Dargham Dopamine hypothesis of schizophrenia: making sense of it all Curr. Psychiatry Rep. 9 2007 329 336
65. G. Tsai, L.A. Passani, B.S. Slusher, R. Carter, L. Baer, J.E. Kleinman, and J.T. Coyle Abnormal excitatory neurotransmitter metabolism in schizophrenic brains Arch. Gen. Psychiatry 52 1995 829 836
66. G. Tsai, P. Yang, L.C. Chung, N. Lange, and J.T. Coyle D-serine added to antipsychotics for the treatment of schizophrenia Biol. Psychiatry 44 1998 1081 1089
67. G.E. Tsai, P. Yang, L.C. Chung, I.C. Tsai, C.W. Tsai, and J.T. Coyle D-serine added to clozapine for the treatment of schizophrenia Am. J. Psychiatry 156 1999 1822 1825
68. M.L. Wadenberg, C. Wiker, and T.H. Svensson Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence Int. J. Neuropsychopharmacol. 10 2007 191 202